This study investigated the relationship between hospital exposures, intestinal microbiota, and subsequent risk of Clostridium difficile-associated disease (CDAD), with use of a nested case-control design. The study included 599 patients, hospitalized from September 2006 through May 2007 in Montreal, Quebec, from whom fecal samples were obtained within 72 h after admission; 25 developed CDAD, and 50 matched controls were selected for analysis. Nonsteroidal anti-inflammatory drugs and antibiotic use were associated with CDAD. Fecal specimens were evaluated by 16S ribosomal RNA microarray to characterize bacteria in the intestinal microbiota during the at-risk period. Probe intensities were higher for Firmicutes, Proteobacteria, and Actinobacteria in the patients with CDAD, compared with controls, whereas probe intensities for Bacteroidetes were lower. After epidemiologic factors were controlled for, only Bacteroidetes and Firmicutes remained significantly and independently associated with development of CDAD. Hospital exposures were associated with changes in the intestinal microbiota and risk of CDAD, and these changes were not driven exclusively by antimicrobial use.
dence of CDAD was estimated to be 6 cases per 1000 patient admissions in 1997, and the incidence has been increasing [3, 4] . The incidence of CDAD increased to 22.5 cases per 1000 patient admissions during the 2003 CDAD outbreak in Quebec, for which the crude mortality rate was 24.8% [3, 5] .
The reported risk factors for CDAD include lengthy hospitalization; underlying disease severity; gastric acid-suppressive agents, such as proton pump inhibitors; and most importantly, antimicrobial use [4] [5] [6] [7] [8] . Antimicrobials are thought to suppress or disrupt the intestinal microbiota, allowing the pathogen to colonize and infect the gut. In an extensive literature review of studies that measured the effect of antimicrobial use on human intestinal microbiota, it is clear that certain classes of antimicrobials have profound effects [9] . In some cases, an overgrowth of C. difficile in the intestine was observed during and immediately after antimicrobial therapy [9, 10] . Many different classes of antimicrobials have been associated with CDAD; however, these associations may also reflect changes in antimicrobial pre- , and . , error; NSAID, nonsteroidal anti-inflam- scribing practices over time [2] . The "classic" model for CDAD pathogenesis therefore involves antimicrobial use followed by disturbances in intestinal microbiota, leading to C. difficile overgrowth and subsequent CDAD. Alternative models of CDAD pathogenesis have recently been proposed. One model (the "cofactor" model), based on epidemiologic evidence, suggests that other cofactors, notably H2-receptor antagonists (H2 blockers) and proton pump inhibitors, may play a role in CDAD pathogenesis [6, [11] [12] [13] [14] ; these effects may occur via antimicrobial-independent and/or antimicrobial-dependent mechanisms. Proton pump inhibitors may enhance the survival of C. difficile through the stomach and may also affect the intestinal microbiota, as evidenced by the diarrhea these agents can sometimes cause [15, 16] ; however, others have presented conflicting evidence regarding proton pump inhibitors [17] . Another alternative model posits that inflammation caused by C. difficile leads to perturbations in the intestinal microbiota, which lead to CDAD development [18] .
The aforementioned models highlight the complexity of measuring intestinal microbiota, for which assays are relatively new, are generally applied in the absence of epidemiologic data, and are often used after disease is already established. In an attempt to address some of these methodologic issues, we employed a 16S ribosomal RNA (rRNA) microarray to test for differences in the predisease composition of intestinal microbiota between persons who subsequently developed CDAD and hospitalized controls, in the context of an epidemiologic study in which patient risk factor information had been collected. We assessed (1) the relationship between epidemiologic covariates (hospital exposures) and risk of CDAD, (2) differences in the premorbid intestinal microbiota between eventual CDAD case patients and controls, and (3) associations between members of the intestinal microbiota and risk of CDAD after controlling for exposure to certain hospital risk factors (Figure 1 ).
METHODS

Study design and sample.
A nested case-control study was conducted. Patients with CDAD and controls were sampled from subjects enrolled in a large cohort study supported by the Fonds de Recherché en Santé du Québec (FRSQ) Clostridium difficile Consortium. The human subjects' protocols for the FRSQ-funded study and the nested study were approved by the Royal Victoria Hospital Internal Review Board and by the McGill University Institutional Review Board (BMB 05-014). Patients were enrolled in the study within 72 h after admission to the ward. Each participant provided his or her written informed consent.
CDAD was defined as (1) the presence of diarrhea and laboratory confirmation of C. difficile with positive toxin assay results (described below), (2) acute diarrhea without an alternate explanation and diagnosis of pseudomembranes, or (3) histologic or pathologic diagnosis of pseudomembranous colitis. Diarrhea was defined as 3 unformed stools within 24 h for у1 day. C. difficile colonization was defined as a positive stool culture or cytotoxin test and the absence of diarrhea. Case patients were matched to controls in a 1:2 ratio according to sex, age ‫5ע(‬ years), and date of hospitalization ‫03ע(‬ days). Patients tended to stay in the hospital longer after an episode of CDAD. We attempted to control for differences in duration of hospitalization by matching controls on the basis of their total duration of hospitalization with case patients on the basis of their time from hospital admission to CDAD diagnosis (defined as the at-risk period).
C. difficile culture and cytotoxin assays. C. difficile culture and cytotoxin assays were used for CDAD diagnosis [19] . C. difficile was confirmed by Gram stain, odor, fluorescence under ultraviolet light, and Microscreen latex agglutination (Microgen Bioproducts) for C. difficile antigen. Toxin B production was assessed by means of a cytotoxin assay using fibroblast cells and was confirmed by neutralization with C. difficile antitoxin (TECHLAB).
Questionnaire. Information on factors hypothesized to be related to either fluctuations in the intestinal microbiota or CDAD was collected in a questionnaire administered to all subjects. These factors included reason for admission, previous hospitalization, underlying disease severity (based on Charlson index) [20] , recent history of diarrhea, use of antimicrobials in the 8 weeks before hospitalization, and use of proton pump inhibitors, H2 blockers, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or probiotics during hospitalization.
Fecal specimen processing. Predisease fecal samples for our study were aliquoted in saline and frozen at Ϫ20ЊC until processed. Fecal specimens were used as a proxy measurement for the intestinal microbiota [21] . Approximately 0.1-1 mg of fecal material from each patient was resuspended in 5 mL of cold 0.05 mol/L potassium phosphate buffer and divided into separate 1-mL aliquots. Total microbial DNA was isolated from patient samples with use of the Promega DNA IQ System (Promega). DNA from the fecal specimens was subjected to wholegenome amplification using the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare). Whole-genome amplification was necessary because of limited fecal material and to ensure adequate DNA quantities for DNA microarray and other testing. Whole-genome amplification with the GenomiPhi kit has been shown to produce unbiased amplified DNA [22] . Amplified DNA was purified using the Invitrogen PureLink PCR Purification Kit.
Broad-range 16S rRNA amplification. A total of 100 ng of purified amplified DNA was used for 16S rRNA polymerase chain reaction (PCR) using broad-range bacterial primer Bact-8F (5 -AGAGTTTGATCCTGGCTCAG-3 ) with universal primer 1391R (5 -GACGGGCGGTGTGTRCA-3 ) or T7-1391R, according to conditions published by Eckburg et al [21] . The reverse primer in the 16S rRNA PCR reaction was tagged with T7 primer so that the amplicon could be used for the transcription reaction with the MEGAscript T7 Transcription Kit (Applied Biosystems/Ambion). 16S rRNA PCR amplicons were purified using the PureLink PCR Purification Kit (Invitrogen). These primers amplify ∼90% of the rRNA coding sequence and minimize PCR bias [21, 23, 24] .
16S rRNA microarray. Oligonucleotides were selected from the published work of Palmer et al [24] , according to the following criteria: either a normalized hybridization signal of 11 for у1 of the samples or a similarity hit of у28 of 40 bases when queried by Basic Local Alignment Search Tool (BLAST) against a database composed of the aggregate 16S rRNA sequences (32,478 total) deposited in GenBank by authors of other studies on human intestinal microbiota [21, 23, 25, 26] . Results from an additional 9 16S rRNA-based studies of intestinal microbial diversity were also used to aid in probe selection [27] [28] [29] [30] [31] [32] [33] [34] [35] . A total of 1412 experimental oligonucleotides were obtained, to which 13 positive and negative control oligonucleotides were added, for a total of 1461 spots. All probes were double spotted on the microarray, and a single array was hybridized for each sample. The experimental microarray probes represent 310 genera, 128 microbial families, and 20 phyla.
In the microarray protocol, ∼100 ng of purified PCR product was used for the transcription reaction with the Ambion MEGAscript T7 High Yield Transcription Kit (Applied Biosystems/ Ambion). Purified RNA (Qiagen RNeasy Mini Kit) was labeled with cyanine 5 (Cy5) with the Mirus Label IT Cy 5 Nucleic Acid Labelling Kit (Mirus Bio). Cy5-labeled RNA was hybridized to the microarray. Microarrays were scanned using the ScanArray Lite Microarray Analysis System (Packard BioChip Technologies), and the images were processed using ScanArray Express software (version 2.1; PerkinElmer).
The microarray data were processed in the following steps. First, probe intensities were log 2 transformed. Normalization of the log 2 -transformed probe intensity data was conducted using the following 2 methods: (1) quantile normalization [36] and (2) global normalization, wherein negative controls were used to adjust for the difference in mean probe intensity between case and control microarrays. The 2 methods of normalization were compared during the analyses, and results were similar (data not shown); we present results based on globally normalized probe intensities, which were more conservative. Probes were classified as being "positive" or "negative" according to their intensity value. For a given array, a probe was said to be negative if its intensity was smaller than the average intensity of the buffer spots plus twice their standard deviation. A probe was said to be negative overall if it was negative for 192% of the case and control arrays (or 69 of the 75 microarrays tested). All overall negative probes (as defined above) were removed from subsequent analyses. If any of the remaining positive probes was classified as negative in a given array, the intensity value for this array and this probe was set to the cutoff value for the array, which was based on the buffer values. Replicate microarrays were performed in 5 samples; correlation coefficients based on intensity levels of replicate arrays were used to assess the reproducibility of results. a Duration until diagnosis of CDAD for case patients or duration until discharge for control subjects.
Validation of the microarray by 16S rRNA sequencing. To assess the validity of the microarray results, the signed rank test was used to compare the rank order (by bacterial family) identified on the microarray with the 16S rRNA sequencing results for 2 samples. The 16S rRNA sequencing was performed using 454 FLX pyrosequencing at the McGill University and Genome Québec Innovation Centre, the same primers and PCR conditions as for the microarray, and established sequencing protocols [37] . Annotation of 16S rRNA sequences was conducted through the Metagenomics RAST server (http://metagenomics.nmpdr.org/).
Intestinal microbiota diversity. The microbial diversity of the intestinal microbiota was compared between case patients and controls. Diversity was evaluated by observed genus or family richness, defined by the total number of positive probes by genus or family in each person. The means of these counts were compared using a t test. The homogeneity of positive probes was also compared between case patients and controls.
Statistical analyses. Analysis was conducted using 3 statistical models (Figure 1 ). First, a preliminary analysis using logistic regression was conducted to determine which epidemiologic covariates were related to CDAD (model 1). Second, a Sign sum is the summation of the signs of the coefficients for probes within bacterial phyla. A large positive value indicates that probe intensities for that phylum are higher among patients with CDAD than among controls; a large negative value indicates that probe intensities are lower among patients with CDAD. The closer the value is to the number of significant probes, the more consistent the results for that phylum. The full model (model 3D) included age, sex, NSAID, and receipt of cephalosporins and fluoroquinolones as covariates.
the intensity for each probe was linearly regressed on disease status with use of logistic regression; this analysis determined which probes were associated with CDAD (model 2). Third, selected covariates were regressed on probe intensity values.
The residuals from this model were obtained for each probe. Finally, the residuals were regressed on disease status with use of logistic regression; this model determined which probes were associated with CDAD after removing the effect of the covariates (model 3). Three nested models were compared with a full model containing all covariates to determine the effect of adjusting for each covariate (models 3A-3C vs 3D, full model).
For models 2 and 3, we recorded the significant probes with a multiple testing strategy based on the false discovery rate; a cutoff of 0.15 for the false discovery rate was used in all analyses [38] . To determine whether the probe intensity was negatively or positively associated with risk of CDAD (models 2 and 3), we took the coefficient for each positive probe and assigned a value of +1 if the value of the model coefficient for that probe was positive or Ϫ1 if that value was negative. These values were summed across all probes within each bacterial phylum or family containing significant (by false discovery rate) probe values (sign sum). The greater the correspondence between the total number of positive probes for each family or phylum and the sum of the sign values (sign sum), the stronger the inference concerning the direction of effect. All data analyses were performed with Stata software (version 11; StataCorp) or R software for statistical computing (http://www.r-project.org).
RESULTS
Sample characteristics.
Of 599 patients enrolled in the FRSQfunded study from September 2006 through May 2007, 31 patients experienced 34 defined episodes of CDAD. Fecal samples were available for 25 patients, and 50 age-and sex-matched controls were selected. One patient with CDAD and the 2 matched controls were excluded because of poor array results despite repeated rehybridizations; this left a total of 72 subjects in the study. Among the case patients, the median duration from hospital admission to disease development did not differ significantly from the median duration from hospital admission to discharge for the controls ( , by Mann-Whitney U P p .61 test). The median interval between stool collection and CDAD diagnosis was 5 days.
16S rRNA microarray. Across the 72 samples, 1165 of 1412 total experimental probes were positive ( Table 1 ). The test-retest reliability of the microarray was evaluated by repeated testing on the same 5 samples on different days. The Pearson correlation coefficients for the log 2 -transformed intensity values for each of the 5 repeated arrays ranged from 0.88 to 0.94. Validation of the microarray by 16S rRNA sequencing. As a further validation of microarray results, we conducted 16S rRNA pyrosequencing on the DNA from a patient with CDAD (33,501 readings) and a control subject (53,443 readings). The signed rank test for the rank order of bacterial families indicated that the ordering produced by sequencing and that produced by the array was the same ( ), although the sequencing P p .92 produced results that were not included on the microarray, as expected. Moreover, only 4 additional families were identified by sequencing, whereas 14 families were identified only by the microarray and not by sequencing. There is a precedent for rRNA microarray testing to have more discriminatory power [39] .
Intestinal microbiota diversity. The observed mean family richness was 62.7 (standard deviation, 17.7) and 53.1 (standard deviation, 13.9) for the patients with CDAD and controls, respectively ( ). When the overlap between positive probes P p .01 was examined for patients with CDAD versus controls, there was no indication that the case patients were more homogeneous (more similar to each other) than controls.
Epidemiologic covariates associated with CDAD (model 1). The distribution of hospital risk factors for case patients and controls is summarized in Table 2 . None of the risk factors from 8 weeks before hospitalization were related to CDAD in this study. Exposures to first-, second-, and third-generation cephalosporins were combined, as were exposures to ciprofloxacin, levofloxacin, moxifloxicin, and gatifloxacin. Candidate risk factors related to CDAD development were evaluated 1 at a time, and CDAD was associated with the use during hospitalization of NSAIDs, fluoroquinolones, or penicillins with blactamase inhibitors (Table 3) .
Relationship between probe intensity and CDAD (model 2). In model 2, we examined the relationship between probe intensities and CDAD by bacterial phylum and family (Table 4 , model 2; Table 5 , family-level analyses). Eight bacterial phyla and 50 bacterial families containing probes were associated with CDAD. Probe intensities for the Firmicutes (which includes C. difficile), Proteobacteria, and Actinobacteria phyla were increased in case patients, compared with controls, whereas those for the Bacteroidetes phylum were lower. The sign sum values for the probes showed consistency when summed; for example, among the Actinobacteria all 33 positive probes had a positive sign, indicating that probe intensities for all Actinobacteriaspecific probes were higher among patients with CDAD than among controls (Table 4) .
Relationship between probe intensity and CDAD after adjustment for covariates (model 3). In the final statistical models, variables included were age, sex, and the use during hospitalization of NSAIDs, cephalosporins, or fluoroquinolones (Table 4 , full model 3D). NSAIDs were selected because exposure was associated with CDAD in model 1. Penicillin with b-lactamase inhibitors use was associated with CDAD in model 1, but it was excluded from the final model because it was closely correlated with fluoroquinolone use. Models 3A, 3B, and 3C should be compared individually with model 3D, containing all covariates. The objective of this analysis was to observe the influence of each covariate on the distribution of bacterial phyla (and families) ( Table 5 ) related to CDAD and, in the full model (model 3D), to determine which bacterial phyla or families remained associated with CDAD after adjustment for epidemiologic covariates. Results are reported by bacterial phylum in Table 4 and by bacterial family in Table 5 .
In the full model (model 3D), only members of the Bacteroidetes and Firmicutes phyla remained significantly associated with risk of CDAD ( Table 4 ). The contrast between models 3A and 3D shows that adjustment for NSAID use produced the largest change in number of positive probes related to CDAD. Contrasting models 3B and 3D shows that fluoroquinolone use also reduces the importance of many of the same bacterial phyla and families affected by NSAID use. In models 3C and 3D, the contribution of cephalosporins is limited. These results suggest that NSAID use and fluoroquinolone use were most strongly associated with changes in the intestinal microbiota that might lead to subsequent CDAD, whereas cephalosporin use on its own was relatively unimportant in this study.
DISCUSSION
The use of NSAIDs, penicillins with b-lactamase inhibitors, or fluoroquinolones during hospitalization was associated with CDAD risk (model 1). Proton pump inhibitor use was not associated with CDAD in this study. The probe intensities corresponding to the bacterial phyla Firmicutes, Proteobacteria, Actinobacteria, and Tenericutes were higher in patients with CDAD than in controls, but probe intensities for the phylum Bacteroidetes were lower (model 2). After adjustment for NSAID and fluoroquinolone use, only a small subset of organisms within the Bacteroidetes and Firmicutes phyla remained significantly and independently associated with CDAD (models 3A-3D; Tables 4 and 5 ). The results of models 2 and 3 show that patient exposure to risk factors, not restricted to antibiotics, may produce important changes in the intestinal microbiota and appear to largely explain the risk of CDAD during hospitalization.
Other studies have examined the relationship between the intestinal microbiota in patients who acquire C. difficile [40] or develop recurrent CDAD [41] [42] [43] . None of these studies examined the influence of epidemiologic risk factors in the analysis of the microbial profiles associated with CDAD. Our results did not confirm reports that low microbial diversity may be related to CDAD development [41] , nor did we find more homogeneous microbiota among patients with CDAD. In these earlier studies, the microbiota were generally assessed at the time of CDAD diagnosis, and findings were probably confounded by the effects of both CDAD-induced inflammation and antimicrobial treatment of CDAD; this may explain the differences between our observations and those of other studies. After adjustment for covariates, we did observe an association between high probe intensities in Lactobacillaceae and Enterococcaceae among patients with CDAD, as reported elsewhere, but we did not observe an association with Enterobacteria [42, 43] .
The observed relationship between NSAIDs, the intestinal microbiota, and CDAD could have several causes. A recent study observed that the total number of microbes in elderly NSAID recipients was higher than that in elderly persons who did not receive NSAIDs, which could mean that NSAIDs have a direct effect on the microbiota [44] . The association could be the result of a reduction in inflammation, leading to an increase in intestinal microbiota diversity. It could result from residual confounding related to the coincident use of proton pump inhibitors or H2 blockers [6, 13] or another widespread cofactor associated with CDAD. Our smaller-than-expected sample size and reduced statistical power may also have led us to miss relationships between specific risk factors and CDAD (eg, proton pump inhibitors).
The microbial complexity of the gut is one reason why studies have made only oblique measurements of the intestinal microbiota while trying to address biologic, clinical, and epidemiologic questions. Comparative metagenomics provides information on the microbial composition and diversity of a community and is beginning to examine the functional or metabolic properties of a community and their impact on the host [45] . Our approach (Figure 1 ) partitions the influence of epidemiologic exposures on the intestinal microbiota and on disease risk. We demonstrated that a combination of risk factors (NSAID and fluoroquinolone use), and not antimicrobial use alone, may lead to an increased risk for CDAD. This finding supports the cofactor hypothesis, which suggests that other hospital exposures or cofactors, such as H2 blocker, proton pump inhibitor, or NSAID use, in conjunction with antimicrobial use, may play a role in CDAD pathogenesis [11, 12, 14] .
